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Abstract
Background: The branched-chain amino acid (BCAA) leucine has been identified to be a key regulator of skeletal
muscle anabolism. Activation of anabolic signalling occurs via the mammalian target of rapamycin (mTOR) through
an undefined mechanism. System A and L solute carriers transport essential amino acids across plasma
membranes; however it remains unknown whether an exogenous supply of leucine regulates their gene
expression. The aim of the present study was to investigate the effects of acute and chronic leucine stimulation of
anabolic signalling and specific amino acid transporters, using cultured primary human skeletal muscle cells.
Results: Human myotubes were treated with leucine, insulin or co-treated with leucine and insulin for 30 min, 3 h
or 24 h. Activation of mTOR signalling kinases were examined, together with putative nutrient sensor human
vacuolar protein sorting 34 (hVps34) and gene expression of selected amino acid transporters. Phosphorylation of
mTOR and p70S6K was transiently increased following leucine exposure, independently to insulin. hVps34 protein
expression was also significantly increased. However, genes encoding amino acid transporters were differentially
regulated by insulin and not leucine.
Conclusions: mTOR signalling is transiently activated by leucine within human myotubes independently of insulin
stimulation. While this occurred in the absence of changes in gene expression of amino acid transporters, protein
expression of hVps34 increased.
Background
Amino acids are essential for the regulation of cell
growth and proliferation [1,2] in two ways; by providing
the substrate required for polypeptide biosynthesis, and
by modulating signalling pathways responsible for pro-
tein synthesis [3-6]. Various cell models have examined
the anabolic potential of the branched chain amino acid
(BCAA), leucine, to stimulate skeletal muscle growth via
mammalian target of rapamycin (mTOR) signalling
[7,8,3,9,10]. Phosphorylation of mTOR complex 1, a
rapamycin-sensitive kinase, is vital for downstream acti-
vation of phosphokinases required for translational
initiation. Stimulation of mTOR by nutrients or insulin
activates p70 ribosomal S6 kinase (p70S6K), a key med-
iator of the protein synthesis cascade [11]. Active
p70S6K subsequently leads to phosphorylation of its
downstream target, ribosomal protein S6 kinase (S6).
This results in the translation of messenger RNA
(mRNA) which encode for ribosomes and transcription
factors, an essential process leading to increased cellular
capacity to undergo protein synthesis [12].M o r e o v e r ,
mTOR-catalysed stimulation of eukaryotic initiation
factor 4E-binding protein (4E-BP1) results in its dis-
association from eukaryotic initiation factor 4E (eIF4E).
Subsequent binding of eIF4E to eIF4G forms the eIF4F
translation initiation complex, and allows the recruit-
ment of the 40S ribosomal subunit to the 5’-end of the
mRNA to initiate protein translation [13].
Despite extensive evidence linking leucine with the
activation of anabolic signalling [14-18,7,19-22,10], the
proximal mechanisms by which mTOR responds to
intracellular levels of leucine remain elusive. To date,
several intermediary ‘nutrient sensing’ molecules, such
as those characterised in Saccharomyces cerevisiae and
bacteria, have been implicated in directing amino acid
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activated protein kinase kinase kinase kinase 3
(MAP4K3), activating proteins Rag 1-4 and class III
phosphatidylinositol 3’-kinase vacuolar protein sorting 34
(Vps34) are thought to converge on signalling through
mTOR in mammalian cells [25-27]. However, recent evi-
d e n c ef r o mr o d e n tm o d e l ss u g g e s t st h a ti ti st h ea c t i v i t y
of Vps34 which is the primary modulator of leucine-sti-
mulated mTOR signalling in rat muscle [28]. Further-
more, it has been previously demonstrated that human
vacuolar protein sorting 34 (hVps34) is required for
nutrient activation of p70S6K, via mTOR signalling [29].
The intricate balance of amino acid influx and efflux
in skeletal muscle is maintained by both system A and
system L transport proteins, which are responsive to
amino acid starvation and hormones [30-32]. Sodium
coupled neutral amino acid transporter 2 (SNAT2), the
predominant system A member expressed in human
skeletal muscle, is reportedly regulated by both insulin
and amino acid deprivation in cultured L6 myotubes
[31,33]. Additionally, leucine exposure following serum
withdrawal causes an enhanced rate of uptake of N-
methylamino-alpha-isobutyric acid (MeAIB), a system A
substrate, by SNAT2 [34]. However, it remains unknown
whether enhanced uptake by SNAT2 occurs via
increased gene transcription, augmented protein synth-
esis of the amino acid transporter or by increased activ-
ity. Similarly, system L-type amino acid transporters
(LAT) have been extensively examined for their possible
role in tumour growth, and exhibit a high affinity for
BCAA [35,36]. Given the extensive evidence describing
the potency of BCAA on mTOR-driven protein synth-
esis in skeletal muscle, no studies to date have examined
the regulation of LAT transporters by amino acids, spe-
cifically BCAA. Identifying the effectiveness of leucine as
a regulator of amino acid transporters within skeletal
muscle will provide further insight in the role these pro-
teins play in the control anabolic signalling.
Therefore in the present study, a human cell culture
model was used to; (1) compare and contrast the effects
of acute and chronic nutrient and hormonal stimulation
of anabolic signalling which occurs in skeletal muscle,
and (2) analyse their ability to modulate protein expres-
sion of the putative nutrient sensor, hVps34, and gene
expression of selected amino acid transporters. It was
hypothesised that leucine stimulated phosphorylation of
mTOR-related signalling kinases would occur together
with activation of hVps34 and amino acid transporter
gene expression.
Results
Confirmation of a homogenous primary myotube culture
Purity of primary myotube cultures was assessed by
immunocytochemical labelling of the muscle cell marker
myogenin (green; Figure 1). A typical purity of 95% was
achieved.
Leucine and insulin independently
regulate mTOR signalling
Leucine and insulin are known activators of mTOR in
human skeletal muscle tissue. Thus the ability of these
stimuli to regulate the expression of phosphorylated
mTOR both individually and together in human myo-
tubes was assessed (Figure 2). Cells treated with leucine
or insulin for 30 min demonstrated a significant increase
in phosphorylated serine mTOR following normalisation
with total mTOR (1.3-fold, P < 0.01 and 1.6-fold; P <
0.05 respectively). Protein abundance of total mTOR did
not change following treatment for all timepoints exam-
ined (Additional file 1, Figure S1). No evidence of syner-
gistic activation of mTOR with combined leucine and
insulin treatment was evident. Conversely, cultures sti-
mulated for 3 h displayed increased mTOR expression
under all treatment conditions, with the greatest
increase observed with insulin stimulation (2.0-fold; P <
0.001). This was found to be maintained with co-treat-
ment of leucine and insulin (2.0-fold; P <0 . 0 1 ) .A t2 4h
the response was diminished, with only insulin-treated
myotubes exhibiting significant increases in mTOR
phosphorylation (1.5-fold; P < 0.01), above baseline.
Protein abundance of putative nutrient sensing
protein, hVps34, is increased in response to
leucine and insulin stimulation
It has been previously suggested that the activation of
anabolic signalling is mediated through the nutrient-sen-
sing protein, hVps34. In order to investigate whether the
BCAA member, leucine, enhances hVps34 protein
expression, hVps34 protein expression was measured in
leucine and insulin-stimulated myotubes (Figure 3).
Immunoblotting revealed that acute exposure (30 min)
was sufficient to significantly increase hVps34 protein
abundance in cells treated with leucine alone (1.3-fold;
P = 0.05) and insulin alone (1.5-fold; P < 0.05). No syner-
gistic effect occurred following co-treatment of leucine
and insulin together. Similar increases were seen follow-
ing 3 h stimulation of leucine (P <0 . 0 0 1 )a n di n s u l i n
(P < 0.001) with significant increases in hVps3 abundance
occurring after co-stimulation of leucine with insulin
(1.5-fold; P < 0.05). hVps34 protein expression remained
elevated following incubation with leucine alone (P <
0.05) and insulin alone (P < 0.05) for 24 h.
Leucine and insulin independently and synergistically
regulate p70S6K signalling
Activation of the downstream effector, p70S6K (Figure
4), occurred in response to both leucine (2.0-fold; P <
0.05) and insulin (2.0-fold; P < 0.01). Co-treatment with
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p70S6K (2.9-fold; P < 0.01) when normalised to total
p70S6K. Interestingly, stimulation of leucine alone for 3
h did not affect levels of phosphorylated p70S6K on
threonine 389, whereas insulin alone did (3.3-fold; P <
0.01). Similar observations occurred when myotubes
were chronically treated for 24 h with insulin (2.7-fold;
P < 0.05). No activation in response to leucine was
detected following 24 h treatment.
Leucine and insulin induce translation initiation via
activation of eIF4G
The effect of leucine and insulin on the activation of
translation initiation was compared by measuring
phosphorylation of eIF4G (Figure 5). Ser1108 phosphor-
ylation significantly increased with 30 min insulin expo-
sure (1.5-fold; P < 0.01) but remained unaltered upon
exposure to leucine when normalised to total eIF4G.
Contrastingly, exposure to leucine alone for both 3h and
24 h, and in combination with insulin, significantly
stimulated signalling through eIF4G.
Insulin but not leucine differentially regulates
amino acid transporters
To assess whether members of the system A and L
transporter families undergo adaptive regulation
following amino acid or insulin treatment, SNAT2,
LAT1, LAT4 and CD98hc gene expression was measured
(Figure 6). SNAT2 and LAT1 mRNA expression was not
altered by leucine or insulin. Conversely, insulin alone
or in combination with leucine resulted in a significant
down-regulation of LAT4 at 3 h and 24 h. Insulin sti-
mulation for 3 h significantly up-regulated CD98hc gene
expression (1.2-fold, P < 0.01), however exposure for 24
h caused a significant decrease (0.3-fold, P < 0.001).
LAT4 mRNA expression was unaltered by leucine
treatment.
Discussion
The aim of this study was to evaluate the anabolic effect
of acute and chronic leucine and insulin stimulation in
a model of human skeletal muscle. It was important to
determine whether leucine could mediate mTOR-related
signalling via activation of the putative regulator,
hVps34, and amino acid transporters. The present work
demonstrates the ability of the BCAA member, leucine,
to independently stimulate mTOR signalling in an
experimental model of human skeletal muscle. Although
p70S6K was only transiently activated by leucine,
chronic stimulation resulted in enhanced phosphoryla-
tion of the ternary kinase, eIF4G. Moreover, these data
offer an explanation of the molecular mechanism by
Figure 1 Cultured human primary myotubes labelled for myogenin. Primary myoblasts were grown to near confluence and induced to
differentiate for 7 days. Myogenin (green) was detected by immunocytochemistry using anti-myogenin antibody followed by anti-mouse Alexa
488 secondary antibody. Scale bar = 30 μm.
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vation of the hVps34 protein. Finally, while exogenous
leucine and insulin were sufficient to stimulate anabolic
signalling in cultured myotubes, incubation did not alter
gene expression of the amino acid transporters
measured.
The use of human primary myotubes provides perti-
nent experimental data on amino acid-mediated ana-
bolic signalling that occurs in human skeletal muscle
tissue. Cultured muscle cells undergo differentiation to
form mature myotubes [37] thus providing a physiologi-
cally relevant model to study molecular signalling events
which occur in vivo. In agreement with data from
rodent studies [17,14,9,20], Chinese hamster ovary cells
(CHO) [38], pancreatic beta-cells [39] and rat hepato-
cytes [40], this study demonstrates for the first time that
mTOR-related signalling kinases are responsive to a
physiological dose of leucine in a human model of skele-
tal muscle, primary myotubes. However, while mTOR
was stimulated by insulin on serine residue 2448, at all
time points measured, the action of leucine was transi-
ent (1.3-fold increase) with phosphorylation diminishing
after 30 min. This is consistent with Deldicque et al.
Figure 2 Leucine and insulin independently regulate mTOR
signalling. Primary human myotubes were untreated or incubated
in the presence of leucine (Leu; 5 mM), insulin (Ins; 100 nM) or co-
treated with leucine and insulin (Leu + Ins) for 30 min (A), 3 h (B) or
24 h (C). Phosphorylation levels of mTOR at Ser2448 were
determined by Western blot analysis relative to total levels of mTOR.
Data are presented as mean ± SEM (n = 6). *P < 0.05, **P < 0.01,
***P < 0.001 versus untreated.
Figure 3 Leucine and insulin supply modulate the protein
abundance of hVps34. Primary human myotubes were untreated
or incubated in the presence of leucine (Leu; 5 mM), insulin (Ins;
100 nM or co-treated with leucine and insulin (Leu + Ins) for 30
min (A), 3 h (B) or 24 h (C). hVps34 protein abundance was
determined by Western blot analysis. Data are presented as mean ±
SEM (n = 6). *P < 0.05, ***P < 0.001 versus untreated.
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activation within C2C12 cells, a model of murine skele-
tal muscle, following an acute 30 min exposure to 5
mM leucine [17]. However, more recently it was
reported that a 2 mM dose of leucine also stimulates
mTOR phosphorylation on Ser2448 by a comparable
magnitude [14]. The downstream biomarker, p70S6K,
followed a similar trend to mTOR phosphorylation.
While leucine demonstrated transient activation of
p70S6K (2.0-fold increase), insulin appeared to stimulate
this kinase at all time points. Previous work has
demonstrated that 5 mM leucine stimulates p70S6K
activation by 10-fold [17] and a 2 mM dose elicits a 5.9-
fold increase [14] within rodent muscle cells. Further-
more, cultured pancreatic beta-cells have been shown to
respond to 3.3 mM of leucine, therefore the stimulatory
effect of leucine on the phosphorylation state of p70S6K
may be specific to the cell model employed where by
different cell types have a varying dose-response to
amino acids [39]. Previous in vitro experiments demon-
strates the synergistic activation of p70S6K in FAO cells
treated with a combination of amino acids with insulin
Figure 4 Effect of leucine, insulin or in combination, on the
phosphorylation state of p70S6K. Primary human myotubes were
untreated or incubated in the presence of leucine (Leu; 5 mM),
insulin (Ins; 100 nM) or co-treated with leucine and insulin (Leu +
Ins) for 30 min (A), 3 h (B) or 24 h (C). Phosphorylation levels of
p70S6K at Thr389 were determined by Western blot analysis relative
to total levels of p70S6K. Data are presented as mean ± SEM (n =
6). *P < 0.05, **P < 0.01, ***P < 0.001 versus untreated.
Figure 5 Effect of leucine, insulin or in combination, on the
activation of eIF4G. Primary human myotubes were untreated or
incubated in the presence of leucine (Leu; 5 mM), insulin (Ins; 100
nM) or co-treated with leucine and insulin (Leu + Ins) for 30 min
(A), 3 h (B) or 24 h (C). Phosphorylation levels of eIF4G at Ser1108
were determined by Western blot analysis relative to total levels of
eIF4G. Data are presented as mean ± SEM (n = 6). *P < 0.05, **P <
0.01, ***P < 0.001 versus untreated.
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exhibit an additive effect of leucine and insulin, despite
utilising the same insulin concentration. While these
experiments were conducted using leucine only, the for-
mer study used a mixture of amino acids. Furthermore,
recent evidence suggests that while the activation of
anabolic signalling is indeed mTOR-dependent, amino
acids may signal through the Rag complex to activate
mTORC1 while insulin requires the Ras homolog
enriched in brain (Rheb) component to regulate
anabolic signalling [42]. Moreover, it has also been pre-
viously shown that deletion of the Ser2448 phosphoryla-
tion site on mTOR did not affect mTOR activity and
was not required for the downstream phosphorylation
of PHAS-1 (4EBP1) or p70S6K in human embryonic
kidney cells [43]. Therefore, it is possible that while
mTOR phosphorylation in this study was transient, the
downstream activation of p70S6K and eIF4G may occur
through an independent signalling mechanism and
requires further research.
Surprisingly, phosphorylation of eIF4G occurred
following 3 h and 24 h treatment of leucine and insulin.
Given that activation of eIF4G is a necessary step during
formation of the translation initiation complex which is
involved in cap dependent translation [13,44], activation
by leucine indicates that protein synthesis may be
initiated without insulin.
hVps34 is postulated to be a nutrient modulator
responsible for signalling to mTOR. Recently, amino
acid regulation of this class III PI3 kinase has been
investigated in murine myotubes [28], HepG2 and CHO
cells [29]. During states of amino acid starvation,
hVps34 demonstrates reduced function. However, this is
restored with the re-addition of amino acids [27,29].
Furthermore, previous reports demonstrate that endo-
genous expression of hVps34 is unresponsive to 1 μM
insulin [29]. Unlike these studies, human primary
muscle cells demonstrated increased hVps34 protein
abundance following acute and chronic stimulation of
leucine with and without 100 nM insulin. The response
Figure 6 Altered expressions of genes associated with amino acid transport. The mRNA expression of SNAT2 (A), LAT1 (B), LAT4 (C) and
associated glycoprotein CD98hc (D) was measured in primary human myotubes incubated with and without the presence of leucine (Leu; 5
mM), insulin (Ins; 100 nM) or co-treated with leucine and insulin (Leu + Ins) for periods indicated. Expression was detected by semi-quantitative
real time polymerase chain reaction (qPCR) using specific oligonucleotide primers. Values are arbitrary units normalised to the expression levels
of reference gene cyclophilin presented as means the means ± SEM (n = 6). *P < 0.05,* * P < 0.01, ***P < 0.001 versus untreated.
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the physiological need of skeletal muscle for insulin-
mediated glucose uptake and for muscle anabolism
[45,46]. Limited studies have investigated the factors
regulating hVps34 expression; however the possibility of
cross-talk with insulin signalling requires further
analysis.
Both system A and L solute carriers may regulate
intracellular amino acid bioavailability within skeletal
muscle [47]. The activity of system A transporters has
been previously demonstrated to be insulin responsive
cultured adipocytes, liver and rat muscle cells [48-50].
However, in cultured human myotubes both acute and
chronic stimulation with insulin failed to increase
SNAT2 and LAT1 gene expression. It is important to
note that the aforementioned studies used supraphysio-
logical doses of insulin, nearly 2-fold greater than the
concentration used in the current study. System L trans-
port proteins are essential for the movement of BCAA
across the cell membrane of skeletal muscle cells [47].
Leucine exposure of human cultured primary muscle
cells did not exert a change in either LAT1 or LAT4
gene expression, despite the specificity of LAT1 for leu-
cine [51]. However, functional expression of LAT1
requires covalent association with the heavy chain of the
CD98 antigen (CD98hc) in plasma membranes [52].
Acute insulin exposure stimulated an increase in
CD98hc mRNA expression, however longer exposure
resulted in suppressed gene expression. The current
study aimed to present exploratory data on the regula-
tion of amino acid transporters by leucine. Given the
physiological need for amino acids in skeletal muscle,
further research is required to delineate the factors
affecting both the protein expression and cellular locali-
sation of amino acid transporters.
Conclusions
The present study provides the first evidence that
mTOR signalling is enhanced in response to an acute
stimulation with the proteinogenic amino acid, leucine,
within cultured human myotubes. While these actions
appear transient at the leucine dose utilised, activation
of mTOR and p70S6K occurred at physiologically
relevant concentrations independently of insulin stimu-
lation. Interestingly, activation of mTOR signalling by
leucine occurred in the absence of changes in the
expression of genes encoding both the system A and
system L carriers, which are responsible for amino acid
transport. Thus, additional analyses are required to
investigate the molecular mechanisms controlling amino
acid transporter expression within skeletal muscle. Of
note was the increased protein expression of hVps34, a
putative leucine-sensitive kinase which intersects with
mTOR. These results demonstrate the need for further
clinical analysis to be performed specifically investigating




Human primary skeletal muscle cells were obtained
from the vastus lateralis muscle of six healthy male
volunteers (24.6 ± 0.4 years). Informed written consent
was obtained from each subject before participation in
the study, after the nature, purpose and risks of the
study were explained. All experimental procedures
involved in this study were formally approved by the
Deakin University Ethics Committee.
Primary human skeletal muscle cell culture
Human primary skeletal muscle cells were cultured as
previously described [53] using the percutaneous needle
biopsy technique [37] modified to include suction [54].
The excised muscle was immersed and extensively
washed in ice-cold Ham’s F-10 medium (Gibco, Invitro-
gen Corporation, California, USA) containing 50 IU/ml
penicillin, and 5 μg/ml streptomycin before being
minced and digested in 0.5% Trypsin/EDTA (Gibco).
The supernatant containing the myoblasts was then col-
lected and the process repeated a further two times to
break down any remaining tissue. Foetal bovine serum
(FBS) (Gibco) was subsequently added to the superna-
tant to a final concentration of 10% (v/v). The superna-
tant was filtered through a 100 μmf i l t e rt or e m o v ea n y
connective tissue and then spun to collect the cells. The
resulting cell pellet was resuspended in primary growth
medium (Hams F-10, 10% FBS, with 50 IU/mL penicil-
lin, 5 μg/mL streptomycin and 2.5 pg/mL fibroblast
growth factor-2 (FGF-2; Promega, Wisconsin, USA))
and then seeded on to an uncoated flask and incubated
at 37°C for 30 minutes to induce fibroblast attachment,
leaving myoblasts suspended in the medium. The med-
ium was then transferred to second uncoated flask for a
further 30 min to allow for any additional fibroblast
attachment. The medium was aspirated and seeded on
to an extracellular matrix-coated (ECM) (Sigma-Aldrich,
New South Wales, Australia) flask. The resulting pri-
mary cell cultures were maintained in primary growth
medium in humidified air at 37°C containing 5% CO2.
To determine culture homogeneity, the expression of
specific myogenic markers (myoD, myogenin and des-
min) was analysed using immunocytochemistry (Figure
1). In all experiments, the minimal myogenic purity was
80% for myoblast preparations [55].
Leucine and insulin stimulation experiments
When cells reached 70% confluence, proliferation med-
ium was replaced with differentiation medium
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tion, cells were serum starved overnight (16 h) prior to
treatment. Myotubes were then exposed to serum-free
media containing an additional 5 mM of water-soluble
L-leucine (Calbiochem, California, USA) ± human insu-
lin (100 nM; Actrapid
®;N o v oN o r d i s k ,A u s t r a l i a )f o r
either 30 min, 3 h or 24 h. Five millimolar was selected
as an appropriate concentration for these experiments
as dose-response studies demonstrated that 5 mM L-
leucine achieved the greatest stimulatory effect (data not
shown). All experiments were conducted on cells at pas-
sage five.
Protein extraction and immunoblot analysis of insulin
signalling kinases
Cells were lysed after 30 min, 3 h and 24 h, in lysis buf-
fer (pH 7.0) containing 20 mM Tris-HCl, 5 mM EDTA,
10 mM Na-pyrophosphate, 100 mM NaF, 2 mM
Na3VO4, 1% Igepal, 10 μg/mL Aprotinin, 10 μg/mL Leu-
peptin, 3 mM Benzamidine and 1 mM PMSF. The
supernatants were rotated for 1 h at 4°C and subse-
quently centrifuged at 14,000 rpm for 15 min with the
resulting supernatant collected into a fresh tube. Protein
concentrations were determined using a BCA Protein
Assay (Pierce, Thermo Scientific, New South Wales,
Australia) with bovine serum albumin (BSA) as
standard.
Protein lysates were denatured in loading buffer con-
taining dithiothreitol (DTT) and separated by sodium
dodecyl sulphate-polyacrylamide gel electrophoresis
(SDS-PAGE). Proteins were then transferred onto
nitrocellulose membrane and blocked at room tem-
perature using 5% (w/v) BSA (Sigma-Aldrich) in tris
buffered saline with 0.1% (v/v) Tween-20 (TBST;
Sigma-Aldrich). The following phospho-specific antibo-
dies were added and incubated overnight at 4°C in
blocking buffer: mTOR
Ser2448,p 7 0 S 6 K
Thr389,e I F 4 G -
Ser1108 (Cell Signaling, Massachusetts, USA) and
hVps34 (Santa Cruz). Membranes were subsequently
washed and then incubated with anti-rabbit HRP-con-
jugated secondary antibody (1:1000; Calbiochem) for 1
h at room temperature. Following this, membranes
were washed repeatedly as before, and proteins visua-
lised using enhanced chemiluminescence (Perkin-
Elmer, Queensland, Australia) on a Kodak 4000MM
Image Station (Kodak, New York, USA) using a CCD
camera. Band density was quantified using Kodak ima-
ging software version 4.5.0 (Kodak). For normalisation,
blots were stripped using Restore Western Blot Strip-
ping buffer™ (Quantum Scientific, Victoria, Australia)
and then subsequently reprobed for total mTOR, total
p70S6K and total eIF4G proteins to verify the relative
amount of analysed proteins.
RNA extraction
RNA was extracted from primary myotubes using TRI-
reagent (Ambion Inc., Texas, USA) after the treatment
period. Chloroform was added to separate phases. Fol-
lowing centrifugation for 15 min at 14,000 rpm, the aqu-
eous layer was removed and an equal volume of
isopropanol added and incubated at -20°C for 1 h. Fol-
lowing RNA precipitation, samples were centrifuged at
14,000 rpm to pellet the RNA. The pellet was washed
with 75% ethanol in diethyl pyrocarbonate (DEPC)-trea-
ted water and then resuspended in nuclease free water
(NFW). Total RNA concentration and quality were
determined using the Nanodrop ND-1000 (Nanodrop
Technologies, Delaware, USA).
cDNA synthesis
F i r s ts t r a n dc D N Aw a sg e n e r a t e df r o m1μgt o t a lR N A
using the High Capacity RNA-to-cDNA kit (Applied
Biosystems) according to manufacturer’s instructions.
Briefly, a 20 μL reaction mixture consisting of 1 μgo f
total RNA, 10 μL of 2X RT Buffer Reaction Mix, 1 μL
of 20X RT Enzyme Mix and a known amount of NFW
and placed into the thermocycler (Hybaid, Thermo
Scientific) with the following temperature and time pro-
tocol: 37°C for 60 min, 95°C for 5 min, and 4°C for 5
min. All synthesised cDNA samples were stored at -20°
C until further analysis.
Semi-quantitative real time PCR (qPCR)
Analysis of gene expression was performed using the
Applied Biosystems 7500 Real-Time PCR system
(Applied Biosystems). cDNA (diluted 1:20) was analysed
using SYBR green fluorescence (Power SYBR Green
Master Mix, Applied Biosystems) and with primer pairs
specific for the gene of interest. Oligonucleotide primers
were designed using Primer Express 3.0 (Applied Biosys-
tems) software and validated using BLAST sequence
alignment and in the absence of primer-dimers and sec-
ondary structures. All oligonucleotides were purchased
from Geneworks (South Australia, Australia). Refer to
Table 1 for primer sequences.
Each reaction contained 8 μL of 2X Sybr green master
mix, 2 μLo ff o r w a r dp r i m e r ,2μL of reverse primer, 6
μL sterile nuclease-free water and 2 μL of cDNA (1.25
ng/μL). All samples were run in triplicate. An initial
cycle of 10 min at 95°C was used to denature the
cDNA, followed by 40 cycles consisting of 95°C for 15 s
and subsequent extension at 60°C for 1 min.
Reference gene normalisation and calculations
Data were analysed using comparative critical threshold
(Ct) method where the amount of target normalised to
the amount of endogenous control is given by 2
-ΔΔCt
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as an endogenous control was examined using the equa-
tion 2
-ΔCt. It was considered an appropriate endogenous
control for this study because no changes in the expres-
sion of this gene were observed (data not shown).
Statistical analysis
Statistical analysis was performed using SPSS version
17.0 for Windows (SPSS Inc., Illinois, USA). Data are
reported as means ± standard error of the mean (SEM).
All data sets were tested for normal distribution and
variance homogeneity using Levene’st e s tf o rE q u a l i t yo f
Variances. A Student’s t-test was used to determine sig-
nificance between the treatment groups. A probability
level of <0.05 was adopted throughout to determine sta-
tistical significance unless otherwise stated.
Additional material
Additional file 1: Protein abundance of total mTOR is not affected
by either leucine or insulin. A figure representing the protein
expression of total mTOR at 30 min, 3 h and 24 h. Primary human
myotubes were untreated or incubated in the presence of leucine (Leu;
5 mM), insulin (Ins; 100 nM) or co-treated with leucine and insulin (Leu +
Ins) for 30 min (A), 3 h (B) or 24 h (C). Protein abundance of total mTOR
was determined by Western blot analysis. Data are presented as mean ±
SEM (n = 6).
Abbreviations
BCAA: branched-chain amino acid; hVps34: human vacuolar protein sorting
34; LAT: L-type amino acid transporter; mTOR: mammalian target of
rapamycin; mRNA: messenger RNA; p70S6K: p70 ribosomal S6 kinase; SNAT2:
sodium coupled neutral amino acid transporter 2
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